Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$53.93 USD
+1.22 (2.31%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $53.96 +0.03 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 301 - 308 ( 308 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Reports Q2:10 Earnings and Provides Update to CK-?357 and omecamtiv mecarbil Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Initiates CK-?357 Peripheral Artery Disease and Claudication Phase IIa Study
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Q1:10 Earnings and Update to CK-?357 Studies and omecamtiv mecarbil Studies
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
CYTK Announces Statistically Significant Results from the CK-20173537 Phase I Trial
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G